Factors associated with optimal (≥80% PDC) TKI adherence
| . | OR . | 95% CI . | P . |
|---|---|---|---|
| Monitored quarters in the first year | |||
| 0 | 1.00 | ||
| 1-2 | 1.14 | 0.79-1.63 | .49 |
| ≥3 | 1.60 | 1.11-2.31 | .01 |
| Age at diagnosis (y) | |||
| 66-69 | 1.00 | ||
| 70-74 | 1.16 | 0.79-1.70 | .45 |
| 75-79 | 0.75 | 0.51-1.10 | .14 |
| 80-84 | 0.78 | 0.51-1.19 | .26 |
| 85-99 | 0.58 | 0.36-0.94 | .03 |
| Sex | |||
| Female | 1.00 | ||
| Male | 1.20 | 0.92-1.58 | .18 |
| Race | |||
| White | 1.00 | ||
| Other | 0.74 | 0.52-1.07 | .11 |
| Year of diagnosis | |||
| 2007-2010 | 1.00 | ||
| 2011-2014 | 1.60 | 1.15-2.22 | .01 |
| 2015-2017 | 1.54 | 1.09-2.19 | .02 |
| Marital status | |||
| Married | 1.00 | ||
| Unmarried | 0.76 | 0.55-1.04 | .08 |
| Unknown | 0.95 | 0.60-1.51 | .83 |
| Region | |||
| Northeast | 1.00 | ||
| West | 1.05 | 0.64-1.72 | .85 |
| Midwest | 0.63 | 0.42-0.95 | .03 |
| South | 0.78 | 0.56-1.10 | .15 |
| Modified Elixhauser comorbidity score | |||
| 0 | 1.00 | ||
| 1 | 1.00 | 0.72-1.40 | .98 |
| ≥2 | 0.98 | 0.69-1.39 | .90 |
| Previous cancer | |||
| No | 1.00 | ||
| Yes | 0.98 | 0.73-1.31 | .88 |
| Previous CVDs | |||
| No | 1.00 | ||
| Yes | 0.88 | 0.64-1.22 | .45 |
| Previous pulmonary diseases | |||
| No | 1.00 | ||
| Yes | 0.89 | 0.46-1.71 | .73 |
| CVD factors∗ | |||
| No | 1.00 | ||
| Yes | 0.73 | 0.49-1.09 | .13 |
| LIS | |||
| No | 1.00 | ||
| Yes | 1.23 | 0.90-1.69 | .20 |
| Yost index | |||
| Fifth quintile (highest SES) | 1.00 | ||
| Fourth quintile | 1.08 | 0.74-1.59 | .68 |
| Third quintile | 1.42 | 0.93-2.17 | .11 |
| Second quintile | 1.44 | 0.92-2.25 | .11 |
| First quintile (lowest SES) | 0.90 | 0.57-1.42 | .64 |
| Unknown | 1.02 | 0.47-2.20 | .97 |
| Influenza vaccine within 12 mo before diagnosis | |||
| No | 1.00 | ||
| Yes | 1.45 | 1.10-1.91 | .01 |
| . | OR . | 95% CI . | P . |
|---|---|---|---|
| Monitored quarters in the first year | |||
| 0 | 1.00 | ||
| 1-2 | 1.14 | 0.79-1.63 | .49 |
| ≥3 | 1.60 | 1.11-2.31 | .01 |
| Age at diagnosis (y) | |||
| 66-69 | 1.00 | ||
| 70-74 | 1.16 | 0.79-1.70 | .45 |
| 75-79 | 0.75 | 0.51-1.10 | .14 |
| 80-84 | 0.78 | 0.51-1.19 | .26 |
| 85-99 | 0.58 | 0.36-0.94 | .03 |
| Sex | |||
| Female | 1.00 | ||
| Male | 1.20 | 0.92-1.58 | .18 |
| Race | |||
| White | 1.00 | ||
| Other | 0.74 | 0.52-1.07 | .11 |
| Year of diagnosis | |||
| 2007-2010 | 1.00 | ||
| 2011-2014 | 1.60 | 1.15-2.22 | .01 |
| 2015-2017 | 1.54 | 1.09-2.19 | .02 |
| Marital status | |||
| Married | 1.00 | ||
| Unmarried | 0.76 | 0.55-1.04 | .08 |
| Unknown | 0.95 | 0.60-1.51 | .83 |
| Region | |||
| Northeast | 1.00 | ||
| West | 1.05 | 0.64-1.72 | .85 |
| Midwest | 0.63 | 0.42-0.95 | .03 |
| South | 0.78 | 0.56-1.10 | .15 |
| Modified Elixhauser comorbidity score | |||
| 0 | 1.00 | ||
| 1 | 1.00 | 0.72-1.40 | .98 |
| ≥2 | 0.98 | 0.69-1.39 | .90 |
| Previous cancer | |||
| No | 1.00 | ||
| Yes | 0.98 | 0.73-1.31 | .88 |
| Previous CVDs | |||
| No | 1.00 | ||
| Yes | 0.88 | 0.64-1.22 | .45 |
| Previous pulmonary diseases | |||
| No | 1.00 | ||
| Yes | 0.89 | 0.46-1.71 | .73 |
| CVD factors∗ | |||
| No | 1.00 | ||
| Yes | 0.73 | 0.49-1.09 | .13 |
| LIS | |||
| No | 1.00 | ||
| Yes | 1.23 | 0.90-1.69 | .20 |
| Yost index | |||
| Fifth quintile (highest SES) | 1.00 | ||
| Fourth quintile | 1.08 | 0.74-1.59 | .68 |
| Third quintile | 1.42 | 0.93-2.17 | .11 |
| Second quintile | 1.44 | 0.92-2.25 | .11 |
| First quintile (lowest SES) | 0.90 | 0.57-1.42 | .64 |
| Unknown | 1.02 | 0.47-2.20 | .97 |
| Influenza vaccine within 12 mo before diagnosis | |||
| No | 1.00 | ||
| Yes | 1.45 | 1.10-1.91 | .01 |
All variables in the table were mutually adjusted in the model.
CVD factors included hypertension, hyperlipidemia, diabetes mellitus, and tobacco use.